Ulysses Neuroscience Ltd is a patient-centric private R&D organization working together with pharmaceutical companies in order to accelerate drug discovery in neuropsychiatric (major depression, anorexia nervosa and schizophrenia) and neurodevelopmental (Fragile X Syndrome and CDKL5 Deficiency Disorders) diseases by using translation clinical and pre-clinical research. Our translational research investigates neurophysiological and molecular mechanisms leading to the synaptic pathology, microtubule dynamics dysregulation and neuroinflammatory events.
Genomenon’s AI-driven Genomic Landscapes deliver a profound understanding of the genetic drivers and clinical attributes of any genetic disease, from neurodegenerative and rare diseases to cancer. This data enables Pharma to accelerate target discovery, identify genetic biomarkers for better clinical trial stratification, and develop CDx for regulatory approval.
Explore the impact of complex neural-glial interactions on cell health and function over time and gain unprecedented access to dynamic neural biology. Discover how scientists around the world are using Axion BioSystems’ next-generation live-cell assay platforms to model disease in vitro. Visit our website to learn how Axion’s simple and sensitive live-cell assays can help accelerate your research and drug discovery.